\
&
Contact us
\
&
Contact us
Partnership website: https://eit-culture-creativity.eu/
EIT has launched a new Knowledge and Innovation Community (KIC) for the Cultural and Creative Sectors and Industries (CCSI) in Europe. This new KIC will unite cultural and creative organisations from business, higher education, and research and beyond in a pan-European innovation ecosystem. Furthermore, this KIC will train this sector’s future entrepreneurs, power its cutting-edge ventures, and deliver innovative solutions to the challenges the Culture and Creative Sectors and Industries are facing.
EIT Culture and Creativity launches calls on a regular basis. These calls focus on activities that have the potential to strengthen entrepreneurship, innovation capacity and accelerate the competitiveness of European Cultural and Creative Sectors and Industries (CCSI) and Europe’s Green, Digital and Social Transitions. You can find them here.
EIT Culture and Creativity has six Co-Location Centres (CLCs) located across Europe with headquarters in Germany. The Co-Location Centres (CLCs) will act as first entry point for organisations interested to join or participate in the activities of EIT Culture and Creativity. Belgian stakeholders can contact CLC North West (Amsterdam, Netherlands) via clc-nw@eit-culture-creativity.eu.
Finally you can also contact the NCP for Culture and Society, manhei.to@fwo.be.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
